circRNA basic information
circBase ID: hsa_circ_0134501
Name: hsa_circ_ZNF117
Synonym: hsa_circ_0134501_CBC1
Host Gene: ZNF117
Genomic location(hg19): -
Genomic location(hg38): -
Subcellular localization: extracellular
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005233
MONDO name: non-small cell lung carcinoma
Disease details: non-small cell lung cancer / NSCLC
Disease DO ID:
 3908
Disease MeSH ID:
 D002289
Disease NCIt ID:
 C2926
Disease ICD11 ID:
 -
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

plasma samples; peripheral blood
Cell lines:

-
In vivo animal model:

-
circRNA-disease information
Expression pattern:
UP
Associated gene: -
Associated microRNA: -
Biological function: Potential plasma biomarker candidate for predicting gefitinib therapeutic effect in NSCLC; hsa_circ_0134501 was differentially expressed and detectable by RT-qPCR, but was not correlated with PFS in this cohort.
Molecular mechanism: No regulatory mechanism was experimentally elucidated; the study focused on plasma expression profiling and biomarker performance for gefitinib efficacy.
Biological pathway or process:

drug resistance (other)
Detected method:
Q
M
Validation methods:

RNase R Treatment; Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis
Clinical significance:

hsa_circ_0134501 showed diagnostic performance for estimating gefitinib therapeutic effect in NSCLC, with AUC 0.71, sensitivity 78.6%, and specificity 67.8%; it was not correlated with PFS.
Description:

hsa_circ_0134501 was identified and RT-qPCR-validated as a plasma circRNA differentially expressed between gefitinib-effective and -ineffective NSCLC patients. It showed moderate ROC performance for predicting treatment effect, but unlike hsa_circ_0109320, it was not associated with PFS in this study.
Confidence score:

0.6895
Other information
Title:

Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer.

Journal: Journal of thoracic disease
Published: 2019
PubMed ID: 31285870
Study type:

combined clinical and bioinformatics study
Data availability: -
Code availability: -